BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 24461315)

  • 61. Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
    Sakr HF; Abbas AM; Haidara MA
    J Basic Clin Physiol Pharmacol; 2018 Jan; 29(1):61-71. PubMed ID: 29161233
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats.
    Yin Y; Liu H; Zheng Z; Lu R; Jiang Z
    Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial.
    Hajiaghamohammadi AA; Ziaee A; Samimi R
    Phytother Res; 2012 Sep; 26(9):1381-4. PubMed ID: 22308054
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
    Nobili V; Manco M; Devito R; Di Ciommo V; Comparcola D; Sartorelli MR; Piemonte F; Marcellini M; Angulo P
    Hepatology; 2008 Jul; 48(1):119-28. PubMed ID: 18537181
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes.
    Shin JY; Kim SK; Lee MY; Kim HS; Ye BI; Shin YG; Baik SK; Chung CH
    Diabetes Res Clin Pract; 2011 Oct; 94(1):156-62. PubMed ID: 21862168
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Effect of apigenin on protein expressions of PPARs in liver tissues of rats with nonalcoholic steatohepatitis].
    Shi T; Zhuang R; Zhou H; Wang F; Shao Y; Cai Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):124-9. PubMed ID: 25880979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vitamin A supplementation, serum lipids, liver enzymes and C-reactive protein concentrations in obese women of reproductive age.
    Farhangi MA; Keshavarz SA; Eshraghian M; Ostadrahimi A; Saboor-Yaraghi AA
    Ann Clin Biochem; 2013 Jan; 50(Pt 1):25-30. PubMed ID: 23148279
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease.
    Chou SC; Chen KW; Hwang JS; Lu WT; Chu YY; Lin JD; Chang HJ; See LC
    Altern Ther Health Med; 2006; 12(3):34-9. PubMed ID: 16708768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients.
    de Luis DA; Aller R; Izaola O; Gonzalez Sagrado M; Conde R
    Nutr Hosp; 2010; 25(5):730-5. PubMed ID: 21336428
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial.
    Magosso E; Ansari MA; Gopalan Y; Shuaib IL; Wong JW; Khan NA; Abu Bakar MR; Ng BH; Yuen KH
    Nutr J; 2013 Dec; 12(1):166. PubMed ID: 24373555
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
    Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
    Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
    Elshazly SM
    Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy.
    de Piano A; Tock L; Carnier J; Oyama LM; Oller do Nascimento CM; Martinz AC; Foschini D; Sanches PL; Ernandes RM; de Mello MT; Tufik S; Dâmaso AR
    Metabolism; 2010 May; 59(5):613-9. PubMed ID: 19942238
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Alami F; Alizadeh M; Shateri K
    Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
    Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
    Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.
    Chen S; Zhao X; Wan J; Ran L; Qin Y; Wang X; Gao Y; Shu F; Zhang Y; Liu P; Zhang Q; Zhu J; Mi M
    Pharmacol Res; 2015 Sep; 99():74-81. PubMed ID: 26032587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.